MedTrace Logo

Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru

NCT05873855 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2025-07-28

No results posted yet for this study

Summary

This digital couples-based HIV/STI prevention intervention project will determine preliminary efficacy to improve uptake of evidence-based strategies and a tailored prevention plan among cisgender male couples who are in a relationship (defined as greater than 3 months or more).

Conditions

  • HIV Infections
  • Hiv
  • Sexually Transmitted Infections (Not HIV or Hepatitis)
  • Sexually Transmitted Diseases
  • Sexual Behavior
  • Risk Reduction

Interventions

BEHAVIORAL

Para ti, para mi, para nosotros (P3)

From day 1 to day 180 (i.e., entire 6-month duration, post baseline) of the pilot trial, participants randomized to the intervention arm will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.

BEHAVIORAL

Waitlist Control Para ti, para mi, para nosotros (P3)

From day 91 to day 180 (i.e., starting after 3-month assessment) of the pilot trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The P3 intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.

Sponsors & Collaborators

  • University of Southern California

    collaborator OTHER

  • Universidad Peruana Cayetano Heredia

    collaborator OTHER

  • Florida International University

    lead OTHER

Principal Investigators

  • Jason W Mitchell, PhD · Florida International University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-27
Primary Completion
2024-04-26
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05873855 on ClinicalTrials.gov